P Raskin, E Allen, P Hollander, A Lewin, RA … - Diabetes Care, 2005 - Am Diabetes Assoc RESULTS—A total of 209 subjects completed the study. At study end, the mean
HbA 1c value was lower in the BIAsp 70/30 group than in the glargine group (6.91
± 1.17 vs. 7.41 ± 1.24%, P < 0.01). The HbA 1c reduction was greater in ... Cited by 323 - Related articles - All 7 versions
M Bayes, X Rabasseda, JR Prous - Methods and findings in experimental and clinical …, 2006 - journals.prous.com Contributing Editors: P. Cole, C. Orellana, JA Vallès, RM a . Antonijoan, KP
Mohana Priya, M. Priya, V. Renuga, R. Sree Lekha, B. Priya, A. Tomillero, G.
Krithiga and E. Banu Rekha. Cited by 148 - Related articles - All 9 versions
AJ Garber, J Wahlen, T Wahl, P Bressler, R … - Diabetes Obesity and Metabolism, 2006 - epgonline.com Methods: Enrolled patients (n ¼ 100, HbA1c !7.5 and 10%) were !18 years of age,
had diabetes !12 months and had received a stable antidiabetic regimen for at
least 3 months [minimum of two oral antidiabetic drugs (OADs) or at least ... Cited by 141 - Related articles - View as HTML - BL Direct - All 10 versions
BO Boehm, JA Vaz, L Brøndsted, PD Home - European journal of internal medicine, 2004 - Elsevier No significant difference was found in mean HbA 1c after 24 months [BIAsp30,
8.35±0.20%; BHI30 8.13±0.16%; adjusted mean difference (BIAsp30−BHI30) 0.03
(90% CI −0.29 to 0.34)%, P=0.89]. The proportion of patients experiencing ... Cited by 65 - Related articles - All 6 versions
JS Christiansen, JA Vaz, Z Metelko, M Bogoev … - Diabetes Obesity and Metabolism, 2003 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 58 - Related articles - BL Direct - All 7 versions
L Niskanen, LE Jensen, J Råstam, L Nygaard … - Clinical therapeutics, 2004 - Elsevier Results: A total of 137 patients were randomized to treatment; 4 were withdrawn
during the 2-week run-in treatment with biphasic human insulin 30. The mean (SD)
characteristics of the remaining 133 patients (79 men, 54 women) were as ... Cited by 52 - Related articles - All 3 versions
S Luzio, G Dunseath, R Peter, V Pauvaday, … - Diabetologia, 2006 - Springer Abstract Aims/hypothesis: The pharmacokinetic and pharmacodynamic properties of
biphasic insulin aspart (BIAsp 30) (30% soluble, 70% protaminated insulin aspart
[IAsp]) and insulin glargine (IGlarg) were compared. Methods: Twelve people ... Cited by 32 - Related articles - BL Direct - All 3 versions
ML Warren, MJ Conway, LJ Klaff, J Rosenstock … - Diabetes research and clinical practice, 2004 - Elsevier Preprandial dosing (within 5 min before meal) and postprandial dosing (15–20
min after meal onset) of NovoLog Mix 70/30 (BIAsp 30, a biphasic formulation of
insulin aspart, 30% soluble and 70% protamine-crystallized) were compared ... Cited by 29 - Related articles - All 10 versions
